ProCE Banner Activity

Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma

Slideset Download
Conference Coverage
Early investigation of lenalidomide in a patient population with a poor prognosis demonstrates tolerability with some durable responses.

Released: June 14, 2016

Expiration: June 13, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals